Aarti Pharmalabs Q1 FY27 Results: Revenue Jumps 42% to INR 535 Crore

Revenue: INR 535 crore (up 42% YoY)
PAT: INR 71 crore (up 49% YoY)

Reader Takeaway: Strong revenue growth driven by core segments, while capacity expansion bolsters future outlook.

What just happened

Aarti Pharmalabs Ltd. has announced its financial results for the first quarter of FY27, reporting a significant 42% year-on-year increase in revenue, reaching INR 535 crore. The company also saw its Profit After Tax (PAT) grow by an impressive 49% year-on-year to INR 71 crore. EBITDA increased by 40% to INR 133 crore.

Why this matters

These strong results indicate healthy demand for Aarti Pharmalabs' products and services, particularly in its key segments like Xanthine derivatives. The growth in PAT suggests improved profitability and operational efficiency. The ongoing capacity expansions signal the company's commitment to future growth and its ability to capitalize on market opportunities.

The backstory

The company's performance is underpinned by its strong position in specific chemical segments. The Xanthine derivatives business, contributing 57% of quarterly revenue, has shown record sales. Aarti Pharmalabs has been strategically investing in expanding its capacities, including debottlenecking efforts and planning new facilities.

What changes now

Aarti Pharmalabs has completed the debottlenecking of its steroid block at Unit 4, Tarapur, increasing capacity by 33%. New Xanthine derivative capacity has also been commercialized. The company announced a INR 149 crore capital expenditure for a new dedicated CDMO block at Atali, which is expected to break ground in Q3 FY27.

Risks to watch

While Xanthine realizations may decline from peaks, management expects volume growth to offset this. CDMO revenue visibility depends on project timelines. Global market conditions and pricing pressures in generic APIs are ongoing areas of focus.

Peer comparison

(No direct peer comparison data available in the filing.)

Context metrics (time-bound)

• Q1 FY27 Revenue: INR 535 crore (vs. INR 375 crore in Q1 FY26)
• Q1 FY27 EBITDA: INR 133 crore (vs. INR 95 crore in Q1 FY26)
• Q1 FY27 PAT: INR 71 crore (vs. INR 48 crore in Q1 FY26)
• Steroid block capacity increase: 33%

What to track next

Investors will be watching the progress of the new CDMO block at Atali and the company's ability to achieve its 40-50% growth guidance for the CDMO business. Monitoring the normalization of Xanthine prices and overall market conditions in generic APIs will also be crucial.